Arcturus Therapeutics Holdings (ARCT) Financials: History & Chart

Arcturus Therapeutics Holdings Inc.(ARCT)

Biotechnology · San Diego, CA

$13.43-1.23 (-8.37%)

Delayed quote: Oct 6, 2026, 10:55 AM EDT

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.

San Diego, CA

109 employees

arcturusrx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Joseph E. Payne

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	23.80M	2.96M	610K	3.08M	17.15M	24.51M	29.38M	21.00M	38.81M
Cost of Goods Sold	4.00M	0.00	658K	0.00	3.34M	0.00	0.00	0.00	0.00
Gross Profit	19.80M	2.96M	-48K	3.08M	13.81M	24.51M	29.38M	21.00M	38.81M
Gross Profit Margin	83.2%	100.0%	-7.9%	100.0%	80.5%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	122.94M	28.50M	29.73M	34.39M	30.32M	36.13M	46.21M	54.39M	49.55M
Research & Development	86.18M	17.52M	20.93M	24.48M	23.27M	29.58M	34.89M	43.78M	39.13M
Selling, General & Administrative	44.22M	10.99M	8.81M	14.03M	10.40M	10.34M	11.31M	12.38M	13.28M
Operating Income (EBIT)	-103.14M	-25.55M	-29.78M	-31.31M	-16.51M	-11.62M	-16.83M	-33.39M	-10.74M
Operating Margin	-433.4%	-863.3%	-4882.0%	-1016.1%	-96.3%	-47.4%	-57.3%	-159.0%	-27.7%
Income Before Tax (EBT)	-93.28M	-23.79M	-26.96M	-29.08M	-13.45M	-9.18M	-14.08M	-30.01M	-7.12M
Interest Income	8.52M	1.82M	1.93M	1.53M	3.23M	2.57M	2.77M	3.21M	7.64M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	9.86M	1.76M	2.82M	2.22M	3.06M	2.44M	2.75M	3.38M	3.62M
Net Income	-93.28M	-23.79M	-26.96M	-29.08M	-13.45M	-9.18M	-14.08M	-30.00M	-6.90M
Income Tax Expense	-4K	0.00	0.00	-4K	0.00	4K	0.00	-4K	-217K
Net Profit Margin	-391.9%	-803.8%	-4420.3%	-943.8%	-78.4%	-37.5%	-47.9%	-142.9%	-17.8%
EBITDA	-100.40M	-24.90M	-29.12M	-30.63M	-15.75M	-10.84M	-16.02M	-32.58M	-9.82M
EBITDA Margin	-421.8%	-841.6%	-4774.1%	-994.0%	-91.8%	-44.2%	-54.5%	-155.1%	-25.3%
Depreciation & Amortization	2.75M	643K	658K	682K	763K	779K	801K	819K	912K
EPS Basic	-3.33	-0.84	-0.95	-1.05	-0.49	-0.34	-0.52	-1.11	-0.26
EPS Diluted	-3.33	-0.84	-0.95	-1.05	-0.49	-0.34	-0.52	-1.11	-0.26
Weighted Average Basic Shares	28.42M	28.42M	28.42M	27.39M	27.19M	27.13M	27.11M	27.00M	27.06M
Weighted Average Diluted Shares	28.42M	28.42M	28.42M	27.39M	27.19M	27.13M	27.11M	27.00M	27.06M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	67.22M	138.39M	157.75M	205.75M	12.36M	9.54M	20.79M	15.75M
Cost of Goods Sold	3.02M	0.00	0.00	0.00	0.00	55.95M	0.00	16.98M
Gross Profit	64.20M	138.39M	157.75M	205.75M	12.36M	-46.41M	20.79M	-1.23M
Gross Profit Margin	95.5%	100.0%	100.0%	100.0%	100.0%	-486.5%	100.0%	-7.8%
Total Operating Expenses	139.15M	234.06M	235.95M	193.58M	215.21M	25.12M	46.30M	37.56M
Research & Development	112.21M	195.16M	192.13M	147.75M	173.76M	57.85M	33.64M	16.98M
Selling, General & Administrative	46.08M	52.82M	52.87M	46.07M	41.45M	25.12M	12.66M	20.58M
Operating Income (EBIT)	-74.95M	-95.67M	-78.20M	12.18M	-202.85M	-71.52M	-25.51M	-21.81M
Operating Margin	-111.5%	-69.1%	-49.6%	5.9%	-1641.3%	-749.8%	-122.7%	-138.5%
Income Before Tax (EBT)	-65.78M	-80.94M	-27.89M	10.64M	-203.67M	-72.15M	-25.99M	-21.79M
Interest Income	10.10M	15.20M	17.36M	2.58M	753K	470K	408K	514K
Interest Expense	N/A	N/A	767K	3.00M	2.67M	831K	854K	186K
Other Income/Expense	9.17M	14.72M	50.31M	-1.53M	-822K	-624K	-478K	26K
Net Income	-65.78M	-80.94M	-29.73M	9.35M	-203.67M	-72.15M	-25.99M	-21.79M
Income Tax Expense	0.00	-4K	1.83M	1.29M	0.00	0.00	0.00	212K
Net Profit Margin	-97.9%	-58.5%	-18.8%	4.5%	-1648.0%	-756.3%	-125.0%	-138.3%
EBITDA	-71.93M	-92.13M	-75.25M	13.70M	-201.66M	-70.64M	-24.83M	-21.23M
EBITDA Margin	-107.0%	-66.6%	-47.7%	6.7%	-1631.7%	-740.6%	-119.4%	-134.8%
Depreciation & Amortization	3.02M	3.54M	2.96M	1.53M	1.19M	882K	684K	582K
EPS Basic	-2.40	-3.00	-1.12	0.35	-7.74	-3.55	-2.13	-2.16
EPS Diluted	-2.40	-3.00	-1.12	0.35	-7.74	-3.55	-2.13	-2.16
Weighted Average Basic Shares	27.39M	27.00M	26.63M	26.45M	26.32M	20.30M	12.07M	10.07M
Weighted Average Diluted Shares	27.39M	27.00M	26.63M	27.09M	26.32M	20.30M	12.07M	10.07M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.